Competition among companies that produce name-brand drugs won't lower prices, suggests new study, which found competition usually leads to higher prices for consumers. Policies to promote competition, such as accelerating approvals, will likely not result in lower prices without structural reforms.

Competition among companies that produce name-brand drugs won't lower prices, suggests new study, which found competition usually leads to higher prices for consumers. Policies to promote competition, such as accelerating approvals, will likely not result in lower prices without structural reforms.: https://ift.tt/2LNiNiB Read more... https://ift.tt/2MtQvJ9